EquityBulls

Latest News

Keywords Selected: CDMO

Stock Report

OneSource Supports Second Generic Semaglutide Approval in Canada
Windlas Biotech Announces ₹47 Crore Share Buyback at ₹1,000 per Share
Saharsh Davuluri takes over as CEO & MD of Neuland and will lead the next phase of CDMO expansion
Morepen Laboratories bags ₹825 Crore Global Deal
Cohance Lifesciences Appoints Yann D'Herve as CEO of CDMO Business, Effective August 1, 2025
OneSource and Xbrane Biopharma Announce Biosimilars Manufacturing Partnership for the Global Markets
Zydus enters global biologics CDMO business, plans to acquire Agenus’ U.S. manufacturing facilities to accelerate development of innovative therapies
Remedium Lifecare Enhances R&D and CDMO, Secures ₹182.7 Crore Export Deal
Vimta Labs Ltd to invest Rs. 50 crores to Biologics CDMO business foray
Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to Earn SBTi Approval for all 3 Scopes
Granules India Announces Closing of Acquisition of Senn Chemicals, Strengthening Capabilities in Peptide Therapeutics and CDMO Services
Medicamen Biotech Limited signs CDMO contract with XGX Pharma
Bajaj Healthcare Limited enters into CDMO contracts for 15 new APIs
Suven to acquire controlling stake in NJ Bio, Inc., an ADC specialist player
Shilpa Medicare Ltd's CDMO customer receives Fast-Track Designation for its investigational drug candidate
OneSource receives equity commitments of INR 8,010 mn from marquee investors at a pre-money equity valuation of USD 1.65 bn
Piramal Pharma Solutions announces $80M Expansion Plan for Sterile Injectables Facility in Lexington, Kentucky
Shilpa's CDMO customer reported positive results from pivotal clinical trial & placed binding purchase order
Bajaj Healthcare Ltd enters into definitive CDMO Agreement for 15 APIs with UK/EU Customers
Advent International announces the completion of the acquisition of Suven Pharma
Coromandel International Ltd enters into Specialty and Industrial Chemicals, foray into CDMO and expansion in Crop Protection Chemicals
Tube Investments of India Ltd forays into Contract Development and Manufacturing Organization
Stelis Biopharma's CDMO partner receives approval for a key ANDA from the USFDA
Stelis Biopharma's two biologics manufacturing facilities receive EU cGMP accreditation